Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20209013 | 0.86 | CYP1A2 (0.67) | CYP1A2SCN5AGRM5DYRK1APIM1 | |
| SCHEMBL26462162 | 0.75 | CYP1A2 (0.50) | CYP1A2SCN5AGRM5DYRK1APIM1 | |
| SCHEMBL20190844 | 0.72 | CYP1A2 (0.55) | CYP1A2SCN5AGRM5DYRK1A | |
| SCHEMBL20191104 | 0.72 | CYP1A2 (0.52) | CYP1A2SCN5AGRM5DYRK1A | |
| SCHEMBL26539129 | 0.70 | CYP1A2 (0.87) | CYP1A2SCN5ADYRK1A | |
| SCHEMBL26462087 | 0.70 | CYP1A2 (0.57) | CYP1A2SCN5A | |
| SCHEMBL20190540 | 0.69 | CYP1A2 (0.70) | CYP1A2SCN5ADYRK1APIM1 | |
| SCHEMBL20188664 | 0.69 | CYP1A2 (0.73) | CYP1A2SCN5ADYRK1APIM1 | |
| SCHEMBL23572551 | 0.69 | CYP1A2 (0.52) | CYP1A2SCN5AGRM5 | |
| SCHEMBL20203838 | 0.69 | CYP1A2 (1.00) | CYP1A2SCN5ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230134428-A1 | FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL | PRAXIS PRECISION MEDICINES, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230134428-A1 | FUSED HETEROARYL COMPOUNDS, AND METHODS THEREOF FOR TREATING DISEASES, DISORDERS, AND CONDITIONS RELATING TO ABERRANT FUNCTION OF A SODIUM CHANNEL | SCN1A, SCN3A, SCN2A | CYP1A2 3251/4885SCN5A 7/4885GRM5 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.